Does the number of metastatic organ involvement affect the response to irinotecan-based chemotherapy in patients with metastatic colorectal | ||
| SECI Oncology Journal | ||
| Article 2, Volume 6, Issue 2, May 2018, Pages 7-15 PDF (888.87 K) | ||
| DOI: 10.21608/secioj.2018.10569 | ||
| Abstract | ||
| Background and objectives: Palliative chemotherapy for colorectal cancer(CRC) is more effective than the best supportive care at prolonging survival and improving quality of life. 5-fluorouracil (FU) and leucovorin (LV) modulation were the standard of care, despite having no major impact on survival.In the 1990s, two additional agents, irinotecan and oxaliplatin, were found to have activity against advanced colorectal cancer and have demonstrated survival improvement, when given either alone or in combination with LV\FU, in first- or second-line therapy. Patients and methods: Prospective study to correlate between response to irinotecan based chemotherapy (FOLFIRI regimen or weekly single agent irinotecan)and the number of metastatic organ involvement in patients with metastatic colorectal cancer as regards responserate and also to compare between FOLFIRI regimen and weekly irinotecan as regards response, survival and toxicity profile in the same patients. Results: There was significant difference between the two used protocol as regards response whereFOLFIRI arm was superior to weekly single irinotecan arm in patients with 4 or more metastatic involved organs (P=0.01). Toxicity profile was somewhat similar except in alopecia and infection where weekly irinotecan was less incidence of infection and more incidence of alopecia. Conclusion: FOLFIRI arm was superior to weekly irinotecan arm as regard the response in patient with 4 or more involved organs. | ||
| Keywords | ||
| FOLFIRI; weekly irinotecan; metastatic CRC; Colon; Rectum | ||
|
Statistics Article View: 97 PDF Download: 124 |
||
